Chronic Obstructive Pulmonary Disease
Conditions
Keywords
safety, pharmacokinetics, spirometry
Brief summary
In MediciNova's clinical development plan for MN-221, it was recognized that treatment of COPD exacerbations may necessitate more than one single i.v. infusion and that patients in this population may have more co-morbidities (and concomitant medications) than has been generally studied so far. Thus, the primary objective of this clinical study is to determine the repeated administration safety and tolerability of intravenous (i.v.) MN-221 compared to placebo with repeated administration over several days in moderate to severe COPD patients who may also have co-morbidities and concomitant medications (CM) common in this population. Secondary outcomes include pharmacokinetics (PK) and preliminary efficacy (FEV1). This Phase 1b trial follows naturally upon a Phase 1b COPD trial completed last year (MN-221-CL-010) and is additionally well-supported by relevant animal safety data and human clinical trial information.
Interventions
DRUGMN-221
This drug is intravenously infused and delivers 1200 mcg to the patient in 1 hour duration. This dose is repeated over 4 days (Day 1 1200 mcg once; Day 2 1200 mcg twice; Day 3 1200 mcg twice; Day 4 1200 mcg once).
DRUGPlacebo
This intervention consists of a placebo intravenous infusion, one that contains no active medication. During the double-blind procedure, patients will be infused with placebo intravenously one time on Day 1, twice on Days 2 and 3, and one time on Day 4.
Sponsors
MediciNova
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
40 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Male or female 40-75 years of age, inclusive; * History of physician-diagnosed (e.g., by clinical history, \>15-pack year history of smoking, physical examination, and spirometry) COPD treated for ≥ 3 months prior to Visit 1 Pre-Screening; * FEV1 ≥ 30% and \< 80% predicted and FEV1/FVC ratio \< 0.7 at Visit 1 Pre-Screening and Visit 2 Screening; * Negative urine pregnancy test for all females unless the subject is post-menopausal (≥ 24 months of spontaneous amenorrhea) or surgically sterile (hysterectomy, bilateral ovariectomy or bilateral tubal ligation); * Negative urine drug screen for cocaine, phencyclidine (PCP), methamphetamine; * Negative alcohol breath test; * Electrocardiogram (ECG) without serious abnormality and with QTcB and QTcF \< 460 milliseconds (msec); * Ability to wash-out of concomitant LABA and Theophylline, if ongoing, for 7-8 days (i.e., Visit 2 Screening through 5-Day Treatment Period). * Legally effective written informed consent obtained prior to starting any study procedures. * Subject willing and able to comply with the protocol and procedures, as judged by Investigator.
Exclusion criteria
* Sustained release methylxanthine (e.g. Theophylline) or long acting beta agonists ≤ 48 hours prior to treatment start (Day 1); * Acute exacerbation of COPD requiring emergency treatment ≤ 30 days of screening or hospitalization ≤ 60 days of Visit 2 Screening; * Antibiotic therapy for respiratory infection ≤ 15 days of Visit 2 Screening; * Presence of active respiratory disease such as pneumonia and acute exacerbation of chronic bronchitis; * Hypokalemia defined as a potassium level \<3.0 mmol/L at Visit 2 Screening. note: Subjects \<3.0 mmol/L may be re-screened at Visit 2 Screening after receiving potassium replacement therapy; * Significant clinical laboratory abnormality that, in the opinion of the Investigator, may put the subject at risk; * Significant renal, hepatic, endocrine, neurologic or other systemic disease that, in the opinion of the Investigator, may put the subject at undue risk; * Uncontrolled hypertension (defined as a blood pressure ≥ 170/100 mm Hg at Visit 1 Pre-Screening) and/or uncontrolled angina, uncontrolled diabetes, uncontrolled congestive heart failure (CHF), uncontrolled serious arrhythmia; * Myocardial infarction within 6 months of treatment start; * Pregnant or lactating females; * Participation in another clinical study with an investigational drug within 30 days of Visit 1 Pre-Screening; * Patients with home oxygen requirements. * A known allergy to excipients of the MN-221 drug product; * A known allergy to other beta agonists; * Currently on medication/s that are recognized to have risk of Torsades de Pointes
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants with Adverse Events as a Measure of Safety and Tolerability | Treatment Days 1- 5 | The recording of AEs will start after the subject has signed the consent form and will end at the Hour 24 phone interview. Investigator(s) will monitor each subject closely for AEs and the Investigator will record all observed or volunteered AEs. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| MN-221 and primary metabolite levels will be analyzed by liquid chromatography/mass spectrometry/mass spectrometry. | Treatment Days 1-5 | Blood samples will be analyzed for MN-221 and primary metabolite levels by liquid chromatography/mass spectrometry (LC/MS/MS. |
| Evaluation of respiratory parameters (FEV1, peak flow, accessory muscle use, respiratory rate) | Screening, Treatment Days 1,3,5 | — |
Countries
United States
Outcome results
None listed